In the evolving landscape of cancer treatment, the advent of immunotherapies Keytruda and Opdivo has marked a groundbreaking shift. Over the last decade, these drugs, known as PD1 inhibitors, have revolutionized oncology, offering new hope and significantly altering patient outcomes. Their story is
Arsenal Biosciences, commonly known as ArsenalBio, has achieved a remarkable milestone by securing $325 million in a Series C funding round. This significant financial boost arrives amid a challenging year for biotech investments, particularly in the cell and gene therapy sectors. The raised
Sanofi, a leading pharmaceutical company, recently announced the results of its clinical trials for tolebrutinib, an experimental drug targeting multiple sclerosis (MS). The mixed outcomes have generated a buzz within the medical and investment communities. While the drug did not outperform an
In a significant development for the pneumococcal vaccine market, Vaxcyte has announced promising results from its Phase 1/2 trials, unveiling a vaccine that has the potential to challenge established leaders like Pfizer's Prevnar 20. The initial data not only showcases impressive efficacy but
Recursion Pharmaceuticals has reached a significant milestone in its journey to develop a treatment for cerebral cavernous malformation (CCM), a complex neurovascular condition. The company's leading experimental drug, REC-994, recently concluded a Phase 2 clinical trial, and the results are
Chronic skin diseases like plaque psoriasis have long posed significant challenges for patients and medical professionals alike, with existing treatments often falling short in efficacy and patient compliance. However, the emergence of Oruka Therapeutics, Inc. is positioned to revolutionize the
